Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 162

1.

Delineating metabolic signatures of head and neck squamous cell carcinoma: phospholipase A2, a potential therapeutic target.

Tripathi P, Kamarajan P, Somashekar BS, MacKinnon N, Chinnaiyan AM, Kapila YL, Rajendiran TM, Ramamoorthy A.

Int J Biochem Cell Biol. 2012 Nov;44(11):1852-61. doi: 10.1016/j.biocel.2012.06.025. Epub 2012 Jun 26.

2.

Magic angle spinning NMR-based metabolic profiling of head and neck squamous cell carcinoma tissues.

Somashekar BS, Kamarajan P, Danciu T, Kapila YL, Chinnaiyan AM, Rajendiran TM, Ramamoorthy A.

J Proteome Res. 2011 Nov 4;10(11):5232-41. doi: 10.1021/pr200800w. Epub 2011 Oct 18.

3.

Chemotherapeutic alteration of VEGF-/PDGF- and PDGF-Rα/β expression by imatinib in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.

Schultz JD, Mühlheim K, Erben P, Hofheinz RD, Faber A, Thorn C, Sommer JU, Hörmann K, Sauter A.

Oncol Rep. 2011 Nov;26(5):1099-109. doi: 10.3892/or.2011.1403. Epub 2011 Jul 26.

PMID:
21805039
4.

Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells.

Sandulache VC, Ow TJ, Pickering CR, Frederick MJ, Zhou G, Fokt I, Davis-Malesevich M, Priebe W, Myers JN.

Cancer. 2011 Jul 1;117(13):2926-38. doi: 10.1002/cncr.25868. Epub 2011 Jan 10.

5.

Acquired resistance to EGFR tyrosine kinase inhibitors alters the metabolism of human head and neck squamous carcinoma cells and xenograft tumours.

Beloueche-Babari M, Box C, Arunan V, Parkes HG, Valenti M, De Haven Brandon A, Jackson LE, Eccles SA, Leach MO.

Br J Cancer. 2015 Mar 31;112(7):1206-14. doi: 10.1038/bjc.2015.86.

6.

Plasma membrane proteomics of tumor spheres identify CD166 as a novel marker for cancer stem-like cells in head and neck squamous cell carcinoma.

Yan M, Yang X, Wang L, Clark D, Zuo H, Ye D, Chen W, Zhang P.

Mol Cell Proteomics. 2013 Nov;12(11):3271-84. doi: 10.1074/mcp.M112.025460. Epub 2013 Jul 31.

7.
8.

Malignancy-associated metabolic profiling of human glioma cell lines using 1H NMR spectroscopy.

Shao W, Gu J, Huang C, Liu D, Huang H, Huang Z, Lin Z, Yang W, Liu K, Lin D, Ji T.

Mol Cancer. 2014 Aug 27;13:197. doi: 10.1186/1476-4598-13-197.

9.

Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.

Amornphimoltham P, Patel V, Sodhi A, Nikitakis NG, Sauk JJ, Sausville EA, Molinolo AA, Gutkind JS.

Cancer Res. 2005 Nov 1;65(21):9953-61.

10.

Persistent activation of Rac1 in squamous carcinomas of the head and neck: evidence for an EGFR/Vav2 signaling axis involved in cell invasion.

Patel V, Rosenfeldt HM, Lyons R, Servitja JM, Bustelo XR, Siroff M, Gutkind JS.

Carcinogenesis. 2007 Jun;28(6):1145-52. Epub 2007 Jan 18.

PMID:
17234718
11.
12.

Identification of TRPC6 as a possible candidate target gene within an amplicon at 11q21-q22.2 for migratory capacity in head and neck squamous cell carcinomas.

Bernaldo de Quirós S, Merlo A, Secades P, Zambrano I, de Santa María IS, Ugidos N, Jantus-Lewintre E, Sirera R, Suarez C, Chiara MD.

BMC Cancer. 2013 Mar 14;13:116. doi: 10.1186/1471-2407-13-116.

13.

Dynamic cellular and molecular modulations of diabetes mediated head and neck carcinogenesis.

Liu CJ, Chang WJ, Chen CY, Sun FJ, Cheng HW, Chen TY, Lin SC, Li WC.

Oncotarget. 2015 Oct 6;6(30):29268-84. doi: 10.18632/oncotarget.4922.

14.

Suppression of squamous cell carcinoma growth and differentiation by retinoids.

Lotan R.

Cancer Res. 1994 Apr 1;54(7 Suppl):1987s-1990s. Review.

15.

Docetaxel associated pathways in cisplatin resistant head and neck squamous cell carcinoma: a pilot study.

Yoo GH, Lin HS, Iskander AJ, Piechocki MP, Oliver J, Kewson D, Lonardo F, Tainsky MA, Kim HR, Kim H, Ensley JF.

Laryngoscope. 2005 Nov;115(11):1938-46.

PMID:
16319602
16.

Pharmacotherapy for squamous-cell carcinoma of the head and neck.

Papaspyrou G, Werner JA, Dietz A.

Expert Opin Pharmacother. 2011 Feb;12(3):397-409. doi: 10.1517/14656566.2011.523698. Review.

PMID:
21254947
17.

Head and neck cancer cells and xenografts are very sensitive to palytoxin: decrease of c-jun n-terminale kinase-3 expression enhances palytoxin toxicity.

Görögh T, Bèress L, Quabius ES, Ambrosch P, Hoffmann M.

Mol Cancer. 2013 Feb 14;12:12. doi: 10.1186/1476-4598-12-12.

18.
19.

Expression profiles and clinical correlations of degradome components in the tumor microenvironment of head and neck squamous cell carcinoma.

Stokes A, Joutsa J, Ala-Aho R, Pitchers M, Pennington CJ, Martin C, Premachandra DJ, Okada Y, Peltonen J, Grénman R, James HA, Edwards DR, Kähäri VM.

Clin Cancer Res. 2010 Apr 1;16(7):2022-35. doi: 10.1158/1078-0432.CCR-09-2525. Epub 2010 Mar 21.

20.

Increased sensitivity to bleomycin in upper aerodigestive tract mucosa of head and neck squamous cell carcinoma patients.

Jin C, Jin Y, Wennerberg J, Rosenquist B, Mertens F.

Mutat Res. 2008 Mar 29;652(1):30-7. doi: 10.1016/j.mrgentox.2007.12.003. Epub 2007 Dec 17.

PMID:
18243046

Supplemental Content

Support Center